Entering text into the input field will update the search result below

Gilead Sciences' Norbert Bischofberger to step down; names new scientific chief and medical chief

  • Gilead Sciences (NASDAQ:GILD) announces that Norbert Bischofberger, PhD, will step down from his role as Executive VP, R&D and Chief Scientific Officer, effective at the end of April.
  • John McHutchison, MD, currently Executive VP, Clinical Research, will be appointed as Chief Scientific Officer.
  • Also, Andrew Cheng, MD, PhD, Executive VP, Clinical Research & Development Operations, will be appointed as Chief Medical Officer.
  • Both will report to John Milligan, PhD, Gilead’s President and CEO.
  • Dr. McHutchison joined Gilead in 2010. Prior to joining Gilead, Dr. McHutchison worked at Duke University Medical Center, where he served as Associate Director of the Duke Clinical Research Institute.
  • Dr. Cheng joined Gilead in 1999 to lead company’s development-stage programs in HIV/AIDS. He was named Executive VP in 2015.

Recommended For You

About GILD Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
GILD--
Gilead Sciences, Inc.